3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective
Advanced Drug Delivery Reviews · 2023
DOI: 10.1016/j.addr.2023.114859 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023. Verfasst von Karen Al-Litani und 3 weiteren Autor:innen. Beteiligte Einrichtung: UCL School of Pharmacy, University College London, WC1N 1AX London, UK. Hauptthemen laut MEDLINE: Drug Delivery Systems, Pharmacy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Higher Education Commision, Pakistan, Higher Education Commission Pakistan.
Abstract (Originalsprache)
Modern pharmaceutical interventions are shifting from traditional "one-size-fits-all" approaches toward tailored therapies. Following the regulatory approval of Spritam®, the first marketed drug manufactured using three-dimensional printing (3DP) technologies, there is a precedence set for the use of 3DP in the manufacture of pharmaceutical products. The involvement of 3DP technologies in pharmaceutical research has demonstrated its capabilities in enabling the customisation of characteristics such as drug dosing, release characteristics and product designs on an individualised basis. Nonetheless, research into 3DP implantable drug delivery devices lags behind that for oral devices, cell-based therapies and tissue engineering applications. The recent efforts and initiatives to address the disparity in women's health is overdue but should provide a drive for more research into this area, especially using new and emerging technologies as 3DP. Therefore, the focus of this review has been placed on the unique opportunity of formulating personalised implantable drug delivery systems using 3DP for women's health applications, particularly passive implants. An evaluation of the current landscape and key formulation challenges for achieving this is provided supplemented with critical insight into the current global regulatory status and its outlook.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL School of Pharmacy, University College London, WC1N 1AX London, UK.
- UCL School of Pharmacy, University College London, WC1N 1AX London, UK; Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi, Pakistan.
- UCL School of Pharmacy, University College London, WC1N 1AX London, UK. Electronic address: pamela-martinez@ucl.ac.uk.
- UCL School of Pharmacy, University College London, WC1N 1AX London, UK; School of Science, Faculty of Engineering and Science, University of Greenwich, ME4 4TB, UK. Electronic address: a.buanz@gre.ac.uk.
Förderung
- Higher Education Commision, Pakistan
- Higher Education Commission Pakistan
Zitieren
APA
Al-Litani, K., Ali, T., Robles Martinez, P., & Buanz, A. (2023). 3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2023.114859
Vancouver
Al-Litani K, Ali T, Robles Martinez P, Buanz A. 3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective. Advanced Drug Delivery Reviews. 2023. doi:10.1016/j.addr.2023.114859
BibTeX
@article{AlLitani2023,
author = {Al-Litani, Karen and Ali, Tariq and Robles Martinez, Pamela and Buanz, Asma},
title = {3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective},
journal = {Advanced Drug Delivery Reviews},
year = {2023},
doi = {10.1016/j.addr.2023.114859}
}
EUVIMED